O	0	7	Lactate	Lactate	NN	B-NP
O	7	8	-	-	HYPH	O
O	8	21	dehydrogenase	dehydrogenase	NN	B-NP
O	22	23	5	5	CD	I-NP
O	24	26	is	be	VBZ	B-VP
O	27	40	overexpressed	overexpresse	VBN	I-VP
O	41	43	in	in	IN	B-PP
B-Cancer	44	47	non	non	AFX	B-NP
I-Cancer	47	48	-	-	HYPH	I-NP
I-Cancer	48	53	small	small	JJ	B-NP
I-Cancer	54	58	cell	cell	NN	I-NP
I-Cancer	59	63	lung	lung	NN	I-NP
I-Cancer	64	70	cancer	cancer	NN	I-NP
O	71	74	and	and	CC	O
O	75	85	correlates	correlate	VBZ	B-VP
O	86	90	with	with	IN	B-PP
O	91	94	the	the	DT	B-NP
O	95	105	expression	expression	NN	I-NP
O	106	108	of	of	IN	B-PP
O	109	112	the	the	DT	B-NP
O	113	126	transketolase	transketolase	NN	I-NP
O	126	127	-	-	HYPH	B-NP
O	127	131	like	like	JJ	I-NP
O	132	139	protein	protein	NN	I-NP
O	140	141	1	1	CD	I-NP
O	141	142	.	.	.	O

O	143	147	AIMS	AIMS	NNS	B-NP
O	147	148	:	:	:	O
O	149	151	As	As	IN	B-SBAR
O	152	155	one	one	CD	B-NP
O	156	158	of	of	IN	B-PP
O	159	162	the	the	DT	B-NP
O	163	167	five	five	CD	I-NP
O	168	175	lactate	lactate	NN	I-NP
O	176	189	dehydrogenase	dehydrogenase	NN	I-NP
O	190	191	(	(	(	O
O	191	194	LDH	LDH	NN	B-NP
O	194	195	)	)	)	O
O	196	206	isoenzymes	isoenzyme	NNS	B-NP
O	206	207	,	,	,	O
O	208	212	LDH5	LDH5	NN	B-NP
O	213	216	has	have	VBZ	B-VP
O	217	220	the	the	DT	B-NP
O	221	228	highest	high	JJS	I-NP
O	229	239	efficiency	efficiency	NN	I-NP
O	240	242	to	to	TO	B-VP
O	243	251	catalyze	catalyze	VB	I-VP
O	252	260	pyruvate	pyruvate	JJ	B-NP
O	261	275	transformation	transformation	NN	I-NP
O	276	278	to	to	TO	B-VP
O	279	286	lactate	lactate	VB	I-VP
O	286	287	.	.	.	O

O	288	292	LDH5	LDH5	NN	B-NP
O	293	307	overexpression	overexpression	NN	I-NP
O	308	310	in	in	IN	B-PP
B-Cell	311	317	cancer	cancer	NN	B-NP
I-Cell	318	323	cells	cell	NNS	I-NP
O	324	331	induces	induce	VBZ	B-VP
O	332	334	an	an	DT	B-NP
O	335	346	upregulated	upregulate	VBN	I-NP
O	347	357	glycolytic	glycolytic	JJ	I-NP
O	358	368	metabolism	metabolism	NN	I-NP
O	369	372	and	and	CC	O
O	373	380	reduced	reduce	VBN	B-NP
O	381	391	dependence	dependence	NN	I-NP
O	392	394	on	on	IN	B-PP
O	395	398	the	the	DT	B-NP
O	399	407	presence	presence	NN	I-NP
O	408	410	of	of	IN	B-PP
O	411	417	oxygen	oxygen	NN	B-NP
O	417	418	.	.	.	O

O	419	423	Here	Here	RB	B-ADVP
O	424	426	we	we	PRP	B-NP
O	427	435	analyzed	analyze	VBD	B-VP
O	436	440	LDH5	LDH5	NN	B-NP
O	441	448	protein	protein	NN	I-NP
O	449	459	expression	expression	NN	I-NP
O	460	462	in	in	IN	B-PP
O	463	464	a	a	DT	B-NP
O	465	469	well	well	RB	I-NP
O	470	483	characterized	characterize	VBN	I-NP
O	484	489	large	large	JJ	I-NP
O	490	496	cohort	cohort	NN	I-NP
O	497	499	of	of	IN	B-PP
B-Cancer	500	507	primary	primary	JJ	B-NP
I-Cancer	508	512	lung	lung	NN	I-NP
I-Cancer	513	520	cancers	cancer	NNS	I-NP
O	521	523	in	in	IN	B-PP
O	524	535	correlation	correlation	NN	B-NP
O	536	538	to	to	TO	B-PP
O	539	546	clinico	clinico	AFX	B-NP
O	546	547	-	-	HYPH	I-NP
O	547	559	pathological	pathological	JJ	I-NP
O	560	564	data	datum	NNS	I-NP
O	565	568	and	and	CC	O
O	569	572	its	its	PRP$	B-NP
O	573	581	possible	possible	JJ	I-NP
O	582	588	impact	impact	NN	I-NP
O	589	591	on	on	IN	B-PP
O	592	599	patient	patient	NN	B-NP
O	600	608	survival	survival	NN	I-NP
O	608	609	.	.	.	O

O	610	617	METHODS	METHODS	NNS	B-NP
O	617	618	:	:	:	O
B-Cancer	619	626	Primary	Primary	JJ	B-NP
I-Cancer	627	631	lung	lung	NN	I-NP
I-Cancer	632	639	cancers	cancer	NNS	I-NP
O	640	641	(	(	(	O
O	641	642	n	n	NN	B-NP
O	643	644	=	=	SYM	B-VP
O	645	648	269	269	CD	B-NP
O	648	649	)	)	)	O
O	650	653	and	and	CC	O
B-Tissue	654	657	non	non	JJ	B-NP
I-Tissue	658	668	neoplastic	neoplastic	JJ	I-NP
I-Tissue	669	673	lung	lung	NN	I-NP
I-Tissue	674	680	tissue	tissue	NN	I-NP
O	681	682	(	(	(	O
O	682	683	n	n	NN	B-NP
O	684	685	=	=	SYM	B-VP
O	686	688	35	35	CD	B-NP
O	688	689	)	)	)	O
O	690	694	were	be	VBD	B-VP
O	695	701	tested	test	VBN	I-VP
O	702	705	for	for	IN	B-PP
O	706	710	LDH5	LDH5	NN	B-NP
O	711	721	expression	expression	NN	I-NP
O	722	724	by	by	IN	B-PP
O	725	745	immunohistochemistry	immunohistochemistry	NN	B-NP
O	746	751	using	use	VBG	B-VP
O	752	753	a	a	DT	B-NP
O	754	764	polyclonal	polyclonal	JJ	I-NP
O	765	769	LDH5	LDH5	NN	I-NP
O	770	778	antibody	antibody	NN	I-NP
O	779	780	(	(	(	O
O	780	787	ab53010	ab53010	NN	B-NP
O	787	788	)	)	)	O
O	788	789	.	.	.	O

O	790	793	The	The	DT	B-NP
O	794	801	results	result	NNS	I-NP
O	802	804	of	of	IN	B-PP
O	805	809	LDH5	LDH5	NN	B-NP
O	810	820	expression	expression	NN	I-NP
O	821	825	were	be	VBD	B-VP
O	826	836	correlated	correlate	VBN	I-VP
O	837	839	to	to	TO	B-PP
O	840	847	clinico	clinico	AFX	B-NP
O	847	848	-	-	HYPH	I-NP
O	848	860	pathological	pathological	JJ	B-NP
O	861	865	data	datum	NNS	I-NP
O	866	868	as	as	RB	B-CONJP
O	869	873	well	well	RB	I-CONJP
O	874	876	as	as	IN	I-CONJP
O	877	879	to	to	TO	B-PP
O	880	887	patient	patient	NN	B-NP
O	887	888	'	'	POS	B-NP
O	888	889	s	s	NN	I-NP
O	890	898	survival	survival	NN	I-NP
O	898	899	.	.	.	O

O	900	902	In	In	IN	B-PP
O	903	911	addition	addition	NN	B-NP
O	911	912	,	,	,	O
O	913	916	the	the	DT	B-NP
O	917	924	results	result	NNS	I-NP
O	925	927	of	of	IN	B-PP
O	928	931	the	the	DT	B-NP
O	932	942	previously	previously	RB	I-NP
O	943	949	tested	test	VBN	I-NP
O	950	963	transketolase	transketolase	NN	I-NP
O	964	968	like	like	IN	B-PP
O	969	970	1	1	CD	B-NP
O	971	978	protein	protein	NN	I-NP
O	979	980	(	(	(	O
O	980	985	TKTL1	TKTL1	NN	B-NP
O	985	986	)	)	)	O
O	987	997	expression	expression	NN	B-NP
O	998	1002	were	be	VBD	B-VP
O	1003	1013	correlated	correlate	VBN	I-VP
O	1014	1016	to	to	TO	B-PP
O	1017	1021	LDH5	LDH5	NN	B-NP
O	1022	1032	expression	expression	NN	I-NP
O	1032	1033	.	.	.	O

O	1034	1041	RESULTS	RESULTS	NNS	B-NP
O	1041	1042	:	:	:	O
O	1043	1045	89	89	CD	B-NP
O	1045	1046	.	.	.	O
O	1046	1047	5	5	CD	B-NP
O	1047	1048	%	%	NN	I-NP
O	1049	1050	(	(	(	O
O	1050	1051	n	n	NN	B-NP
O	1052	1053	=	=	SYM	B-VP
O	1054	1057	238	238	CD	B-NP
O	1057	1058	)	)	)	O
O	1059	1061	of	of	IN	B-PP
B-Cancer	1062	1067	NSCLC	NSCLC	NN	B-NP
O	1068	1076	revealed	reveal	VBD	B-VP
O	1077	1081	LDH5	LDH5	NN	B-NP
O	1082	1092	expression	expression	NN	I-NP
O	1093	1100	whereas	whereas	IN	B-PP
O	1101	1105	LDH5	LDH5	NN	B-NP
O	1106	1116	expression	expression	NN	I-NP
O	1117	1120	was	be	VBD	B-VP
O	1121	1124	not	not	RB	I-VP
O	1125	1133	detected	detect	VBN	I-VP
O	1134	1136	in	in	IN	B-PP
B-Tissue	1137	1140	non	non	JJ	B-NP
I-Tissue	1141	1151	neoplastic	neoplastic	JJ	I-NP
I-Tissue	1152	1156	lung	lung	NN	I-NP
I-Tissue	1157	1164	tissues	tissue	NNS	I-NP
O	1165	1166	(	(	(	O
O	1166	1167	n	n	NN	B-NP
O	1168	1169	=	=	SYM	B-VP
O	1170	1172	34	34	CD	B-NP
O	1172	1173	)	)	)	O
O	1174	1175	(	(	(	O
O	1175	1176	p	p	NN	B-NP
O	1177	1178	<	<	SYM	B-ADJP
O	1179	1180	0	0	CD	B-NP
O	1180	1181	.	.	.	I-NP
O	1181	1185	0001	0001	CD	I-NP
O	1185	1186	)	)	)	O
O	1186	1187	.	.	.	O

O	1188	1192	LDH5	LDH5	NN	B-NP
O	1193	1207	overexpression	overexpression	NN	I-NP
O	1208	1211	was	be	VBD	B-VP
O	1212	1222	associated	associate	VBN	I-VP
O	1223	1227	with	with	IN	B-PP
O	1228	1240	histological	histological	JJ	B-NP
O	1241	1245	type	type	NN	I-NP
O	1246	1247	(	(	(	O
B-Cancer	1247	1261	adenocarcinoma	adenocarcinoma	NN	B-NP
O	1262	1263	=	=	SYM	B-VP
O	1264	1266	57	57	CD	B-NP
O	1266	1267	%	%	NN	I-NP
O	1267	1268	,	,	,	O
B-Cancer	1269	1277	squamous	squamous	JJ	B-NP
I-Cancer	1278	1282	cell	cell	NN	I-NP
I-Cancer	1283	1292	carcinoma	carcinoma	NN	I-NP
O	1293	1294	=	=	SYM	B-VP
O	1295	1297	45	45	CD	B-NP
O	1297	1298	%	%	NN	I-NP
O	1298	1299	,	,	,	O
B-Cancer	1300	1305	large	large	JJ	B-NP
I-Cancer	1306	1310	cell	cell	NN	I-NP
I-Cancer	1311	1320	carcinoma	carcinoma	NN	I-NP
O	1321	1322	=	=	SYM	B-VP
O	1323	1325	46	46	CD	B-NP
O	1325	1326	%	%	NN	I-NP
O	1326	1327	,	,	,	O
O	1328	1329	p	p	NN	B-NP
O	1330	1331	=	=	SYM	B-VP
O	1332	1333	0	0	CD	B-NP
O	1333	1334	.	.	SYM	I-NP
O	1334	1337	006	006	CD	I-NP
O	1337	1338	)	)	)	O
O	1338	1339	.	.	.	O

O	1340	1342	No	No	DT	B-NP
O	1343	1354	significant	significant	JJ	I-NP
O	1355	1366	correlation	correlation	NN	I-NP
O	1367	1372	could	could	MD	B-VP
O	1373	1375	be	be	VB	I-VP
O	1376	1384	detected	detect	VBN	I-VP
O	1385	1389	with	with	IN	B-PP
O	1390	1396	regard	regard	NN	B-NP
O	1397	1399	to	to	TO	B-PP
O	1400	1403	TNM	TNM	NN	B-NP
O	1403	1404	-	-	HYPH	B-NP
O	1404	1409	stage	stage	NN	I-NP
O	1409	1410	,	,	,	I-NP
O	1411	1418	grading	grading	NN	I-NP
O	1419	1421	or	or	CC	I-NP
O	1422	1430	survival	survival	NN	I-NP
O	1430	1431	.	.	.	O

O	1432	1433	A	A	DT	B-NP
O	1434	1437	two	two	CD	I-NP
O	1438	1443	sided	sided	JJ	I-NP
O	1444	1455	correlation	correlation	NN	I-NP
O	1456	1463	between	between	IN	B-PP
O	1464	1467	the	the	DT	B-NP
O	1468	1478	expression	expression	NN	I-NP
O	1479	1481	of	of	IN	B-PP
O	1482	1487	TKTL1	TKTL1	NN	B-NP
O	1488	1491	and	and	CC	I-NP
O	1492	1496	LDH5	LDH5	NN	I-NP
O	1497	1502	could	could	MD	B-VP
O	1503	1505	be	be	VB	I-VP
O	1506	1511	shown	show	VBN	I-VP
O	1512	1513	(	(	(	O
O	1513	1514	p	p	NN	B-NP
O	1515	1516	=	=	SYM	B-VP
O	1517	1518	0	0	CD	B-NP
O	1518	1519	.	.	SYM	I-NP
O	1519	1522	002	002	CD	I-NP
O	1522	1523	)	)	)	O
O	1524	1530	within	within	IN	B-PP
O	1531	1534	the	the	DT	B-NP
O	1535	1542	overall	overall	JJ	I-NP
O	1543	1549	cohort	cohort	NN	I-NP
O	1550	1552	as	as	RB	B-CONJP
O	1553	1557	well	well	RB	I-CONJP
O	1558	1560	as	as	IN	I-CONJP
O	1561	1564	for	for	IN	B-PP
O	1565	1569	each	each	DT	B-NP
O	1570	1577	grading	grading	NN	I-NP
O	1578	1581	and	and	CC	I-NP
O	1582	1584	pN	pN	NN	I-NP
O	1585	1590	group	group	NN	I-NP
O	1590	1591	.	.	.	O

O	1592	1593	A	A	DT	B-NP
O	1594	1605	significant	significant	JJ	I-NP
O	1606	1617	correlation	correlation	NN	I-NP
O	1618	1625	between	between	IN	B-PP
O	1626	1630	LDH5	LDH5	NN	B-NP
O	1631	1634	and	and	CC	I-NP
O	1635	1640	TKTL1	TKTL1	NN	I-NP
O	1641	1647	within	within	IN	B-PP
O	1648	1652	each	each	DT	B-NP
O	1653	1663	histologic	histologic	JJ	I-NP
B-Cancer	1664	1673	tumortype	tumortype	NN	I-NP
O	1674	1679	could	could	MD	B-VP
O	1680	1683	not	not	RB	I-VP
O	1684	1686	be	be	VB	I-VP
O	1687	1695	revealed	reveal	VBN	I-VP
O	1695	1696	.	.	.	O

O	1697	1708	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1708	1709	:	:	:	O
O	1710	1714	LDH5	LDH5	NN	B-NP
O	1715	1717	is	be	VBZ	B-VP
O	1718	1731	overexpressed	overexpresse	VBN	I-VP
O	1732	1734	in	in	IN	B-PP
B-Cancer	1735	1740	NSCLC	NSCLC	NN	B-NP
O	1741	1744	and	and	CC	O
O	1745	1750	could	could	MD	B-VP
O	1751	1756	hence	hence	RB	I-VP
O	1757	1762	serve	serve	VB	I-VP
O	1763	1765	as	as	IN	B-PP
O	1766	1768	an	an	DT	B-NP
O	1769	1779	additional	additional	JJ	I-NP
O	1780	1786	marker	marker	NN	I-NP
O	1787	1790	for	for	IN	B-PP
O	1791	1801	malignancy	malignancy	NN	B-NP
O	1801	1802	.	.	.	O

O	1803	1814	Furthermore	Furthermore	RB	B-ADVP
O	1814	1815	,	,	,	O
O	1816	1820	LDH5	LDH5	NN	B-NP
O	1821	1831	correlates	correlate	VBZ	B-VP
O	1832	1842	positively	positively	RB	B-ADVP
O	1843	1847	with	with	IN	B-PP
O	1848	1851	the	the	DT	B-NP
O	1852	1862	prognostic	prognostic	JJ	I-NP
O	1863	1869	marker	marker	NN	I-NP
O	1870	1875	TKTL1	TKTL1	NN	I-NP
O	1875	1876	.	.	.	O

O	1877	1880	Our	Our	PRP$	B-NP
O	1881	1888	results	result	NNS	I-NP
O	1889	1896	confirm	confirm	VBP	B-VP
O	1897	1898	a	a	DT	B-NP
O	1899	1904	close	close	JJ	I-NP
O	1905	1909	link	link	NN	I-NP
O	1910	1917	between	between	IN	B-PP
O	1918	1921	the	the	DT	B-NP
O	1922	1925	two	two	CD	I-NP
O	1926	1935	metabolic	metabolic	JJ	I-NP
O	1936	1943	enzymes	enzyme	NNS	I-NP
O	1944	1947	and	and	CC	O
O	1948	1956	indicate	indicate	VBP	B-VP
O	1957	1959	an	an	DT	B-NP
O	1960	1970	alteration	alteration	NN	I-NP
O	1971	1973	in	in	IN	B-PP
O	1974	1977	the	the	DT	B-NP
O	1978	1985	glucose	glucose	NN	I-NP
O	1986	1996	metabolism	metabolism	NN	I-NP
O	1997	1999	in	in	IN	B-PP
O	2000	2003	the	the	DT	B-NP
O	2004	2011	process	process	NN	I-NP
O	2012	2014	of	of	IN	B-PP
O	2015	2024	malignant	malignant	JJ	B-NP
O	2025	2039	transformation	transformation	NN	I-NP
O	2039	2040	.	.	.	O

